Nuvalent Inc. (NUVL) has announced positive pivotal data from the global ARROS-1 study of Zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC and is planning to initiate a rolling New Drug Application soon.
ARROS-1 is a Phase 1/2 clinical trial evaluating the company's lead drug candidate, Zidesamtinib, for patients with advanced ROS1-positive NSCLC and other solid tumors. ROS1-positive lung cancer develops when the ROS1 gene fuses with an adjacent gene. This type of lung cancer is typically aggressive and has the potential to metastasize to the brain and bones - Source: Lung Cancer Foundation of America.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.